A Sept.11 article about U.S. biotech company BioArts halting its commercial cloning business stated that the company's hiring of Hwang Woo-suk, a South Korean cloning expert, was a ``plan B'' option, as company CEO Lou Hawthorne initially preferred to secure the services of another Korean scientist, Lee Byeong-cheon, instead. However, in an emailed statement to The Korea Times, Mr. Hawthorne said that Hwang was his first choice and that he has ``no regrets'' about the decision. Mr. Hawthorne said ``I met with both without a preference for either, but once I had met both it was obvious that Hwang was the master and Lee was the student.'' ― ED.